Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) — LEIDEN, The Netherlands – September 8, 2014 – Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that the full data from its exploratory, double-blind, placebo-controlled Phase II study (DEMAND II/ DMD114117/ NCT01153932) of… Continue reading Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
Blog posts
Kiadis Pharma appoints Jeroen Rovers as its Chief Medical Officer
Clinical and Business Development expert re-joins the Company Amsterdam, The Netherlands, September 3, 2014 – Kiadis Pharma B.V. (“Kiadis Pharma”, “Kiadis” or “the Company”), a clinical stage biopharmaceutical company developing T-cell immunotherapy treatments for blood cancers, today announces the appointment of Dr. Jeroen Rovers, MD PhD, as its Chief Medical Officer. Jeroen Rovers was most… Continue reading Kiadis Pharma appoints Jeroen Rovers as its Chief Medical Officer
Prosensa and CureDuchenne Strengthen Long-term Collaboration with an Additional €5M to Advance DMD Pipeline
Leiden, The Netherlands, Aug. 11, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, today announced that an affiliate of CureDuchenne, a US national nonprofit organization dedicated to finding a cure for Duchenne Muscular Dystrophy (DMD), will provide Prosensa with up… Continue reading Prosensa and CureDuchenne Strengthen Long-term Collaboration with an Additional €5M to Advance DMD Pipeline
Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million
Leiden, The Netherlands, July 7, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today confirmed that on July 3 (one year following the closing of its IPO), it filed a shelf registration statement with the US Securities and Exchange Commission.… Continue reading Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million
Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments
Preparing for anticipated launch of lead compound for DMD Leiden, The Netherlands, June 30, 2014 (GLOBE NEWSWIRE) — Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, today announced the appointment of Willem W. van Weperen to the new position of chief commercial officer and… Continue reading Prosensa Strengthens its Management Team and Supervisory Board with Key Appointments
